

The growth differentiation factor-15 (GDF-15) can be useful in the detection of distant metastases in sera of colorectal cancer patients

Jakubowska K.^{1B,C,D}, Pryczynicz A.^{2A,C,E}, Dymicka-Piekarska V.^{3B,C}, Cepowicz D.^{4B}, Jagodzińska D.^{2C}, Lewczuk Ł.^{2C}, Lebelt A.^{5B}, Ozimkiewicz M.^{2B}, Kiszło P.^{3C}, Guzińska-Ustymowicz K.^{2A, E, F*}

1. Department of Pathomorphology, Comprehensive Cancer Center, Białystok, Poland,
2. Department of General Pathomorphology, Medical University of Białystok, Poland
3. Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Poland
4. 2nd Department of General Surgery and Gastroenterology, Medical University of Białystok, Poland
5. Department of Human Anatomy, Medical University of Białystok, Poland

A - Conception and study design, B - Data collection, C –Data analysis, D - Writing the paper, E – Review article, F - Approval of the final version of the article

ABSTRACT

Purpose: Growth differentiation factor-15 (GDF-15) protein belongs to a transforming growth factor- β family which determines the growth and differentiation of cells. In cancers, GDF-15 influences on the proliferation, differentiation, viability, migration and invasiveness of cancer cells. The aim of our study was to evaluate the expression of GDF-15 in the tissue and its levels in sera of patients with colorectal cancer.

Materials and methods: The level of GDF-15 in the sera of 55 patients diagnosed with colorectal cancer was determined using the ELISA method whereas expression of this protein was performed by immunohistochemical method.

Results: The mean value of GDF-15 levels in the sera of patients with colorectal cancer was

significantly higher than in healthy control group ($p < 0.001$). The expression of GDF-15 in the tissue was weak, moderate and strong in 23.6%, 15.7% and 60.7% cases, respectively. Statistical analysis showed that the expression of GDF-15 correlated with patients' age ($p < 0.005$) and non-mucinous type of cancer ($p < 0.001$). The high GDF-15 levels in the serum was associated with tumor size ($p < 0.01$) and distant metastases ($p < 0.05$).

Conclusions: According to our results, we postulate that the level of GDF-15 in serum can be used to assess the metastatic behavior of colorectal cancer.

Key words: Colorectal cancer, Growth differentiation factor-15, macrophage inhibitory cytokine-1, serum.

***Corresponding author:**

Katarzyna Guzińska-Ustymowicz

Department of General Pathomorphology, Medical University of Białystok

13 Waszyngtona Street, 15-269 Białystok, Poland

Tel/Fax: +48-85-7485996; e-mail: kguzinska74@gmail.com

Received: 03.03.2016

Accepted: 22.03.2016

Progress in Health Sciences

Vol. 6(1) 2016 pp 40-48

© Medical University of Białystok, Poland

INTRODUCTION

Colorectal cancer (CRC) is one of the most common malignancies among the Polish population and its morbidity rate is still growing. Due to high mortality rate it is the second cause of death due to malignancies in men and third in women [1]. Risk factors include genetic predispositions, the presence of various intestinal diseases and environmental factors [2]. The CRC incidence in Poland is estimated to increase twice in men and by 1/3 in women within the next few years [3]. Detection of early neoplastic lesions is very rare. Despite prophylactic colorectal cancer screening, these tumors often infiltrate the muscle layer into the subserous membrane of the intestinal wall, and are accompanied by lymph node involvement or distant metastases. Tumors with mucus-secreting cells have much worse prognosis [4]. CRC patients undergo surgical treatment with adjuvant therapy, which reduces complaints and decreases the risk of relapse [5]. However, the 5-year survival rate in patients with advanced lesions is low and despite widely available prophylactic examinations colorectal cancer still remains a diagnostic challenge, its early detection being too rare [6]. Therefore, detailed studies are undertaken to investigate the pathomechanism of CRC growth, including processes of proliferation, differentiation and metastasizing.

Growth/differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1 (MIC-1), prostate-derived factor (PDF), placental TGF- β (PTGF- β), placental bone morphogenetic protein (PLAB) or non-steroidal autoinflammatory drug-activated gene-1 (NAG-1), belongs to the TGF- β family of proteins. Members of this family are responsible for growth and differentiation of cells during embryogenesis and in adult tissues [7,8]. This protein occurs mainly in the placenta, but is also found in the mammary, prostate glands, lung, liver, gastrointestinal tract, pancreas and kidney [9,10]. GDF-15 is involved in the maintenance of homeostasis in normal cells, but also plays a role in pathological conditions, such as cell stress, sudden injury, inflammatory reaction and neoplastic process [11,12].

GDF-15 plays pleiotropic functions in cancer cells. It originates both from cancer cells and from the extracellular matrix enclosing them [13]. The complex of GDF-15 with latent TGF- β -binding protein-1 helps maintain stability of MMP and conditions their expression in breast cancer and kidney cancer cell lines. Therefore, GDF-15 takes part in extracellular remodeling and tissue permeability, conditions metastasizing and regulates tumor growth [14]. Due to its chemopreventive activity, the protein is thought to be mainly responsible for growth inhibition and apoptosis of cancer cells [15,16]. GDF-15

overexpression in epithelial cancer cells has been shown to be associated with a drop in their viability and tumor growth inhibition [17,18]. On the other hand, this protein is responsible for proliferation of cancer cells and tumor vascularization [19,20]. It has been also found that the increase in GDF-15 expression is related to the greater metastatic capacity in cell lines of gastric and breast cancer [21]. Moreover, GDF-15 has been found to cause local and distant metastases to the liver, kidneys and bones in prostate cancer cells [22,23]. Perhaps, GDF-15, due to its significant involvement in the growth and progression of various types of cancers, will become a prognostic marker also in CRC patients. Therefore, the objective of the current study was to assess GDF-15 expression in the tissue and serum of CRC patients.

MATERIALS AND METHODS

Patients

The study group consisted of 55 patients (20 women and 35 men) treated surgically in the 2nd Department of General and Gastroenterological Surgery in the Medical University of Bialystok. The pathological diagnosis confirmed colorectal cancer and its stage (TNM) according to WHO classification. The adenocarcinoma type was diagnosed in 48 individuals, whereas adenocarcinoma with mucous component was identified in 7 individuals. The investigated tumors were classified as moderately differentiated (G2) in 48 patients, and poorly differentiated (G3) in 7 patients. The pT1 tumor was observed in 1 case, pT2 in 3 patients, pT3 in 49 patients and pT4 in 2 patients. At the time of the diagnosis, metastases to local lymph nodes were observed in 29 out of 55 cases, whereas the presence of metastases to distant organs was noted in 25 out of 55 of the studied cases. The control group consisted of 22 healthy volunteers (12 males and 10 females aged 45-75).

Study material consisted of serum samples obtained from both the blood of the patients with colorectal carcinoma collected prior to the surgery and the healthy controls. Blood serum was stored at -80°C immediately after centrifugation until the assay was performed.

The study received the approval of the local Bioethics Committee. All the participants (study group and controls) signed informed consent forms prior to the examination.

Enzyme-linked immunosorbent assay (ELISA)

GDF-15 level was determined by means of the enzyme-linked immunosorbent assay (ELISA) method. Serum samples were prepared according to the manufacturer's instructions. Prior to the assay, the samples were 100-fold diluted with Calibrator Diluents. A monoclonal antibody specific for

GDF-15 had been pre-coated onto a microplate and incubated with serum samples. After the first washing, an enzyme-linked polyclonal antibody specific for GDF-15 was added to the wells. Following the second wash, a substrate solution was added. Next, the color development was stopped. The reaction measurement was based on the intensity of the sample color. All the specimens were assayed twice. No statistically significant differences between the measurements were found. The minimum detectable dose (MDD) of GDF-15 ranged from 0.0 to 4.4 pg/mL. Mean MDD was 2.0 pg/mL. The serum GDF-15 level was expressed in picogram per milliliter (pg/mL).

Immunohistochemistry

The immunohistochemistry method was carried out 38 of 55 patients with colorectal cancer. Formalin-fixed and paraffin-embedded tissue specimens were cut on a microtome into 4 µm sections. The sections were deparaffinized in xylenes and hydrated in alcohols. To visualize the antigens of GDF-15 protein, the sections were heated in a microwave oven for 20 min in a citrate buffer (pH=6.0). Then, they were incubated with 3% hydrogen peroxide solution for 5 min in order to block endogenous peroxidase. Next, incubation was performed with polyclonal rabbit antibody against human GDF-15 (Acris Antibodies, No AP07912PU-N, dilution 1:50) and incubated at 4°C temperature over night. The reaction was carried out using Novocastra Novolink Polymer Detection System (NCL- Novocastra, Leica Biosystems). A

colour reaction for peroxidase was developed with chromogene DAB. The expression of investigated protein was found in cytoplasm of the tumour cells and determined using the semiquantitative method. Expression was defined in relation to the intensity of staining (0 - absent, 1 - weak, 2 - moderate, 3 - strong) and the percentage of positive tumour cells (0-lack of reaction, <10%-weak, 10-50%-moderate, > 50%- strong).

Statistical analysis

Statistical analysis was conducted based on the STATISTICA 10.0 program. In order to compare the two groups, the U Mann-Whitney test was used. Correlations between the parameters were calculated by the Spearman's correlation coefficient tests. The value of $p < 0.05$ was considered statistically significant. The missing data was removed in pairs. The analysis of ROC curve was performed using MedCalc statistical software.

RESULTS

The levels of GDF-15 in the sera of patients with colorectal cancer and healthy controls

The mean serum level of GDF-15 was 2307.23 pg/mL (range 613.55-6300.00 pg/mL) and was statistically significantly higher as compared to healthy volunteers (1305.62 pg/mL; range 274.48-5285.24 pg/mL) (Table 1).

Table 1. The level of GDF-15 protein in the serum of patients with colorectal cancer and healthy controls

	N	GDF-15 (pg/mL)				P- value
		Mean	Median	SD	Range	
Normal	22	1305.62	832.07	1175.12	274.48-5285.24	<0.01
Tumor	55	2307.23	1638.31	1623.58	613.55-6300.00	

Mann-Whitney U-test. Missing data is removed in pairs

The relationship between diagnostic sensitivity and specificity of GDF-15 levels was assessed by ROC curve analysis. The discrimination between colorectal cancer patients (n=55) and healthy controls (n=22) showed an area under ROC curve for GDF-15 was 0.76 (Standard Error^a, 0.066; $p < 0.001$) (Figure 1a). A ROC curve for GDF-15 as a discriminator between colorectal

cancer patients with distant metastases (n=25) and cancer subjects without distant metastases (n=30) showed an area under ROC curve to be 0.70 (Standard Error^a, 0.074; $p < 0.0074$). (Figure 1b).

No statistical significance was noted between the serum level of GDF-15 and its expression in the tissue of CRC patients.




Figure 1. ROC curve analysis for GDF-15: (a) as a discriminator between colorectal cancer subjects healthy controls (AUC-0.76; $p<0.001$), (b) colorectal patients with distant metastasis via carcinoma subjects without distant metastases (AUC-0.70; $p=0.0074$).






Figure 2. Immunohistochemical expression of GDF-15 in colorectal cancer tissue. The positive reactions were strong (a,b), moderate (c) and weak (d) in cytoplasm of cancer cells. Original magnification 200x for a,b,c; 100x for d.



Correlations between the levels of GDF-15 in the sera of patients with CRC and chosen clinicopathological parameters

The serum level of GDF-15 was found to correlate with tumor size ($p<0.05$). In patients with $<5\text{cm}$ tumor, the serum level of the protein was significantly higher. Moreover, increased level of GDF-15 was noted to show a positive correlation with the presence of distant metastases in CRC patients ($p<0.05$). No other correlations were observed of serum GDF-15 with such parameters as age, sex, location, histological type, malignancy grade, tumor stage, Duke's classification and local lymph node involvement. Details are shown in (Table 2).

The correlation between serum GDF-15 concentrations and morphological blood parameters in patients with CRC

The serum level of GDF-15 in CRC patients showed a negative correlation with the level of sodium ($p<0.01$) and positive correlation with potassium ($p<0.01$). The level of sodium was decreasing and that of potassium increasing along with a rise in serum GDF-15.

Table 2. The correlations between the GDF-15 levels in serum and clinical-pathological parameters in patients with colorectal cancer

Parameter		GDF-15 (pg/mL)				
		N	Median	Range	Coefficient	P-value
Age	≤60	19	2202.25	638.67-6300	0.042	NS
	>60	36	2362.64	613.55-6300		
Gender	Male	35	2186.85	638.67-6300	-0.099	NS
	Female	20	2517.89	613.55-6300		
Localization	Colon	33	2360.78	681.37-6300	0.002	NS
	Rectum	22	2370.04	638.67-6300		
Adenocarcinoma type	Nonmucinous	48	2281.40	638.67-6300	0.129	NS
	Mucinous	7	2898.82	724.07-6300		
Grade of malignancies	2	48	2402.36	638.67-6300	-0.106	NS
	3	7	1815.13	724.07-2952		
Tumor size	<5cm	30	2203.93	638.67-6300	0.367	<0.01
	>5cm	25	2553.19	724.07-6300		
pT stage	1	1	1638.31	-	0.195	NS
	2	3	1615.70	638.67-2592		
	3	49	2311.88	681.37-6300		
	4	2	4138.69	1977.38-6300		
Duke stage	A	2	1138.49	681.37-1638	0.228	NS
	B	16	2223.37	638.30-6300		
	C	14	1568.82	1022.95-3665		
	D	23	2854.71	613.55-6300		
Lymph node metastasis	Absent	24	2485.48	638.67-6300	0.462	NS
	Present	29	2233.74	681.37-6300		
Distant metastasis	Absent	30	1889.23	638.67-6300	0.294	<0.05
	Present	25	2848.61	613.55-6300		
IHC expression of GDF-15 in cancer cells	Weak	9	2828.42	1103.32-6300	-0.201	NS
	Moderate	6	1972.86	638.67-		
	Strong	23	2011.60	4664.84 681.37-6300		

Spearman’s correlation coefficient test. Missing data is removed in pairs. NS- non significant

Statistical analysis revealed a positive correlation between the serum level of the protein and aspartate transaminase ($p < 0.01$). Moreover, when the level of GDF-15 increased, glucose level in the blood decreased ($p < 0.05$) (Table 3).

The expression of GDF-15 in colorectal cancer tissue and its association with selected clinicopathological parameters

GDF-15 expression was observed in the cytoplasm of cancer cells. It was weak, moderate or strong in 23.6% (9/38), 15.7% (6/38) and 60.7% (23/38), respectively (Figure 2). In statistical analysis, the expression of GDF-15 correlated with patients’ age ($p < 0.005$). GDF-15 expression increased in patients over 60. A rise in the protein expression was also noted in the tissue of patients with mucinous type cancer ($p < 0.001$) (Table 4).

Table 3. The correlations between the level of GDF-15 protein in serum and morphological blood parameters

Parameter	GDF-15		
	N	Coefficient	P- value
Red Blood Cell Count	29	-0.085	NS
White Blood Cell Count	29	0.200	NS
PLT	29	0.238	NS
Hematocrit	29	-0.121	NS
Hemoglobin	29	-0.161	NS
Sodium	29	-0.497	<0.01
Potassium	29	0.468	<0.01
Prothrombin time	29	-0.076	NS
Wsk protr	28	0.013	NS
Total proteins	20	0.370	NS
Aspartate Transaminase	22	0.621	<0.01
Alanine Transaminase	22	0.094	NS
Glucose	13	-0.552	<0.05
Urea	26	-0.042	NS
Creatinine	23	-0.192	NS

Spearman’s correlation coefficient test. Missing data is removed in pairs. NS- non significant.

Table 4. The correlations between the GDF-15 expression in tumor tissue and clinical-pathological parameters in patients with colorectal cancer

Parameter		GDF-15 expression (Number of cases/ percentage)			p value
		Absent/weak	Moderate	Strong	
Age	≤60	1 (2.6%)	5 (13.1%)	7 (18.4%)	<0.005
	>60	8 (21%)	1 (2.6%)	16 (41.3%)	
Gender	Male	3 (7.8%)	2 (5.2%)	10 (27%)	NS
	Female	6 (15.7%)	3 (7.8%)	13 (36.5%)	
Localization	Colon	4 (10.5%)	2 (5.2%)	18 (46.7%)	NS
	Rectum	5 (13.1%)	4 (10.5%)	5 (13.1%)	
Adenocarcinoma type	Nonmucinous	7 (18.4%)	6 (15.7%)	22 (58.1%)	<0.001
	Mucinous	2 (5.2%)	0 (0%)	1 (2.6%)	
Grade of malignancies	2	8 (21%)	6 (15.7%)	21 (55.2%)	NS
	3	0 (0%)	0 (0%)	2 (5.2%)	
Tumor size	<5cm	3 (7.8%)	4 (10.5%)	13 (36.5%)	NS
	>5cm	5 (13.3%)	2 (5.2%)	9 (26.8%)	
pT stage	1	0 (0%)	0 (0%)	1 (2.6%)	NS
	2	0 (0%)	1 (2.6%)	2 (5.2%)	
	3	8 (21%)	15 (39.4%)	20 (52.6%)	
Duke stage	A	0 (0%)	1(2.6%)	1 (2.6%)	NS
	B	2 (5.2%)	2 (5.2%)	7 (18.4%)	
	C	2 (5.2%)	2 (5.2%)	6 (15.7%)	
	D	4 (10.5%)	1 (2.6%)	9 (26.8%)	
Lymph node metastasis	Absent	4 (10.5%)	3 (7.8%)	9 (26.8%)	NS
	Present	5 (13.1%)	3 (7.8%)	13 (36.5%)	
Distant metastasis	Absent	4 (10.5%)	5 (13.1%)	14 (33.9%)	NS
	Present	5 (13.1%)	1 (2.6%)	9 (26.8%)	

Spearman’s correlation coefficient test. Missing data is removed in pairs. NS- non significant

DISCUSSION

According to recent literature data, GDF-15 protein is present in various types of cancer cells, and its expression and level in body fluids increase as compared to normal control [12,24]. We found markedly higher serum level of GDF-15 in CRC patients than in healthy volunteers. In turn, Brown et al. [25] noted a rise in serum level of GDF-15 both in patients with adenomic polyposis and CRC as compared to healthy subjects. Later, this author also confirmed the rise in patients with polyps in comparison with polyp-free subjects [26]. Research conducted to assess the serum level of GDF-15 in CRC patients showed a gradual increase in the subsequent stages of tumor advancement [27].

Colorectal cancer growth is a complex process, closely associated with secretion of numerous factors of growth, angiogenesis and stromal enzymes [28,29]. It has been proven that GDF-15 plays a double role in the neoplastic process [30]. This protein can decrease viability of HCT-116 colon cancer cell line *in vitro* and inhibit tumor growth *in vivo* [17,18]. In turn, observations of gastric cancer cell lines revealed that GDF-15 conditioned substantial invasiveness of these cells *in vitro* [31]. In our study, the serum level of GDF-15 was found to increase along with a growing tumor diameter. This seems to confirm the protein involvement in tumor progression and its increased level may indicate further expansion of cancer. However, our analysis did not show any statistical significance between serum GDF-15 and TNM. The correlation was confirmed in a study conducted by Brown et al. [25], in which the serum level increased along with TNM stage. Similar findings have been also reported in the plasma of CRC patients [27].

The likelihood of metastasizing increases with rapid tumor growth and its further spread in the stroma. Serum level of GDF-15 has been proven to correlate with the presence of distant metastases in various types of cancers [22,23]. We also observed the correlation between serum level of GDF-15 with CRC and the presence of distant metastases. Our observations remain in accordance with the findings reported by Brown et al. [25], showing the protein increase in CRC patients with metastases as compared to non-metastatic carcinoma. The risk of metastases in these patients also increased when they had D Allele of GDF-15. Moreover, these authors have shown that the assessment of serum GDF-15 together with TNM stage, lymph node involvement and A allele of GDF-15 can be an independent predictive factor of metastases in CRC patients [25]. Xue et al. [32] confirmed the correlation between serum GDF-15 in CRC patients and lymph node involvement.

Moreover, the assessment of GDF-15 and other available diagnostic markers has shown high specificity [22-23,25]. However, the analysis of ROC curve confirmed that GDF-15 shows pretty high specificity and sensitivity as a prognostic parameter in CRC patients. As revealed by the analysis of the field under the ROC curve, serum GDF-15 in CRC patients may allow detection of metastases using simple ELISA test. Our results concerning serum level of GDF-15 in CRC patients confirm that this protein is involved in CRC, determining tumor mass growth in the primary focus and the ability of cancer cells to metastasize.

Moreover, in our study the serum level of the protein was found to correlate with such blood parameters as the level of potassium, sodium, glucose and asparinian transferase. Perhaps, the stimulation of growth factors in neof ormation, including GDF-15, disturbs the whole organism and thus changes the level of body fluid parameters. However, no reports have confirmed our observations.

The presence of GDF-15 has also been confirmed by research concerning its expression in the tissues of patients with CRC and colon cancer cell lines [17,18,33-35]. Proapoptotic properties have been indicated in human colorectal cell lines and antitumorogenic activity in the development of colorectal cancer in the Gdf15 transgenic overexpression mouse model [18,21]. The assessment of GDF-15 gene expression has revealed that this protein is up-regulated in colonic adenomas as compared to normal glands [36]. Our immunohistochemical assessment of the protein showed moderate or strong cytoplasmic expression in most CRC patients. Also, Wallin et al. [27] have noted increased expression of GDF-15 in cancer cells as compared to the normal intestinal epithelium. The above findings seem to be consistent with the observations made by Brown et al. [25], who found a strong protein reaction in the cytoplasm of tumor cells in 90% of cases. In our study, the statistical analysis revealed a correlation between the elevated expression of GDF-15 and age and non-mucinous type of tumor. In turn, Wallin et al. [27] noted a relationship between the increased protein expression and vascular invasion. Moreover, they also observed increased expression of GDF-15 in the primary tumor as compared to metastases in stage III patients. As revealed by immunohistochemical evaluation of the increased expression of GDF-15, the protein takes part in colorectal carcinogenesis and probably conditions its spread.

CONCLUSIONS

Concluding, GDF-15 plays a key role in the development of colorectal cancer, which seems

to be confirmed by the results of our immunohistochemical study and assessment of its serum level in CRC patients. Moreover, determination of serum GDF-15 is strictly related to distant metastases, which may allow application of this protein as a prognostic metastatic marker in colorectal cancer patients. However, broader studies are required, based on a larger group of patients, to prove a definite diagnostic value of serum GDF-15 in the clinical assessment of CRC patients.

Conflicts of interest

None declared.

FUNDING

The study was supported by the Medical University of Białystok, grant No. 133-14660P. The study was approved by the Ethical Committee of the Medical University of Białystok and each subject gave informed written consent before participation in the study.

REFERENCES

1. Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2009 roku. Centrum Onkologii- Instytut im. Marii Skłodowskiej-Curie, Warszawa, 2011.
2. Rasool S, Kadla SA, Rasool V, Ganai BA. A comparative overview of general risk factors associated with the incidence of colorectal cancer. *Tumour Biol.* 2013 Oct; 34(5):2469-76.
3. Didkowska U, Wojciechowska J, Zatoński W. Prognozy zachorowalności na wybrane nowotwory złośliwe w Polsce do 2025. Centrum Onkologii- Instytut im. Marii Skłodowskiej-Curie, Warszawa, 2009.
4. Imai Y, Yamagishi H, Fukuda K, Ono Y, Inoue T, Ueda Y. Differential mucin phenotypes and their significance in a variation of colorectal carcinoma. *World J Gastroenterol.* 2013 Jul; 19(25):3957-68.
5. Minsky BD, Cohen AM, Enker WE, Saltz L, Guillem JG, Paty PB, Kelsen DP, Kemeny N, Ilson D, Bass J, Conti J. Preoperative 5-Fu, low-dose leucovorin and radiation therapy for locally advanced and unresectable rectal cancer. *Int J Rad Oncol Biol Phys.* 1997 Jan;37(2):289-95.
6. Nelson H, Petrelli N, Carlin A. Guidelines 2000 for colon and rectal cancer surgery. *J Natl Cancer Inst.* 2001 Apr;93(8):583-96.
7. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. *Proc Natl Acad Sci USA.* 1997 Oct;94(21):11514-9.
8. Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L. PLAB, a novel placental bone morphogenetic protein. *Biochim Biophys Acta.* 1997 Oct;1354(1):40-4.
9. Yokoyama-Kobayashi M, Saeki M, Sekine S, Kato S. Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta. *J Biochem.* 1997 Sep;122(3):622-6.
10. Kim KS, Baek SJ, Flake GP, Loftin CD, Calvo BF, Eling TE. Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. *Gastroenterology.* 2002 May;122(5):1388-98.
11. Schober A, Böttner M, Strelau J, Kinscherf R, Bonaterra GA, Barth M, Schilling L, Fairlie WD, Breit SN, Unsicker K. Expression of growth differentiation factor-15/ macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. *J Comp Neurol.* 2001 Oct;439(1):32-45.
12. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF Jr, Hampton GM. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. *Proc Natl Acad Sci U S A.* 2003 Mar;100(6):3410-5.
13. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M, Liu T, Smith D, Kuffner T, Pankhurst GJ, Johnen H, Russell PJ, Barret W, Stricker PD, Grygiel JJ, Kench JG, Henshall SM, Sutherland RL, Breit SN. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. *Cancer Res.* 2005 Mar;65(6):2330-6.
14. Abd El-Aziz SH, Endo Y, Miyamaori H, Takino T, Sato H. Cleavage of growth differentiation factor 15 (GDF15) by membrane type 1-matrix metalloproteinase abrogates GDF15-mediated suppression of tumor cell growth. *Cancer Sci.* 2007 Sep;98(9):1330-5.
15. Lincová E, Hampl A, Pernicová Z, Starsichová A, Krčmár P, Machala M, Kozubík A, Soucek K. Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs. *Biochem Pharmacol.* 2009 Sep;78(6):561-72.
16. Zimmers TA, Gutierrez JC, Koniaris LG. Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. *J Cancer Res Clin Oncol.* 2010 Apr;136(4):571-6.
17. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ. Placental transforming growth factor-beta is a

- downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. *J Biol Chem.* 2000 Jun;275(26):20127-35.
18. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. *Mol Pharmacol.* 2001 Apr;59(4):901-8.
 19. Huh SJ, Chung CY, Sharma A, Robertson GP. Macrophage inhibitory cytokine-1 regulates melanoma vascular development. *Am J Pathol.* 2010 Jun;176(6):2948-57.
 20. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, Fairlie DW, Breit SN, Paralkar VM, de Tribolet N, Van Meir EG, Hegi ME. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. *Oncogene.* 2002 Jun;21(27):4212-9.
 21. Kim KK, Lee JJ, Yang Y, You KH, Lee JH. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. *Carcinogenesis.* 2008 Apr;29(4):704-12.
 22. Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, Batra SK. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. *Oncogene.* 2010 Mar; 29(9):1293-302.
 23. Wakchoure S, Swain TM, Hentunen TA, Bauskin AR, Brown DA, Breit SN, Vuopala KS, Harris KW, Selander KS. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. *Prostate.* 2009 May; 69(6):652-61.
 24. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL, Henshall SM, Horvath LG. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. *Cancer Res.* 2009 Oct; 69(19):7696-703.
 25. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, Breit SN. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. *Clin Cancer Res.* 2003 Jul;9(7):2642-50.
 26. Brown DA, Hance KW, Rogers CJ, Sansbury LB, Albert PS, Murphy G, Laiyemo AO, Wang Z, Cross AJ, Schatzkin A, Danta M, Srasuebkul P, Amin J, Law M, Breit SN, Lanza E. Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer? *Cancer Epidemiol Biomarkers Prev.* 2012 Feb;21(2):337-46.
 27. Wallin U, Glimelius B, Jirstrom K, Darmanis S, Nong RY, Pontén F, Johansson C, Pahlman L, Birgisson H. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. *Br J Cancer.* 2011 May;104(10):1619-27.
 28. Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. *Cell Mol Life Sci.* 2011 Dec;68(23):3853-68.
 29. Hagland HR, Berg M, Jolma IW, Carlsen A, Soreide K. *Molecular Pathways and Cellular Metabolism in Colorectal Cancer.* *Dig Surg.* 2013;30(1):12-25.
 30. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. *Cancer Res.* 2003 Aug;63(15):4648-55.
 31. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. *J Cell Physiol.* 2010 Sep;224(3):626-35.
 32. Xue H, Lü B, Zhang J, Wu M, Huang Q, Wu Q, Sheng H, Wu D, Hu J, Lai M. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. *J Proteome Res.* 2010 Jan; 9(1):545-55.
 33. Proutski I, Stevenson L, Allen WL, McCulla A, Boyer J, McLean EG, Longley DB, Johnston PG. Prostate-derived factor--a novel inhibitor of drug-induced cell death in colon cancer cells. *Mol Cancer Ther.* 2009 Sep; 8(9):2566-74.
 34. Baek SJ, Kim JS, Jackson FR, Eling TE, McEntee MF, Lee SH. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. *Carcinogenesis.* 2004 Dec;25(12):2425-32.
 35. Shin SY, Kim JH, Lee JH, Lim Y, Lee YH. 2'-Hydroxyflavanone induces apoptosis through Egr-1 involving expression of Bax, p21, and NAG-1 in colon cancer cells. *Mol Nutr Food Res.* 2012 May;56(5):761-74.
 36. Buckhaults P, Rago C, St Croix B, Romans KE, Saha S, Zhang L, Vogelstein B, Kinzler KW. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. *Cancer Res.* 2001 Oct;61(19):6996-7001.